Vectorized Treg-depleting αCTLA-4 elicits antigen cross-presentation and CD8(+) T cell immunity to reject ‘cold’ tumors

BACKGROUND: Immune checkpoint blockade (ICB) is a clinically proven concept to treat cancer. Still, a majority of patients with cancer including those with poorly immune infiltrated ‘cold’ tumors are resistant to currently available ICB therapies. Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4)...

Descripción completa

Detalles Bibliográficos
Autores principales: Semmrich, Monika, Marchand, Jean-Baptiste, Fend, Laetitia, Rehn, Matilda, Remy, Christelle, Holmkvist, Petra, Silvestre, Nathalie, Svensson, Carolin, Kleinpeter, Patricia, Deforges, Jules, Junghus, Fred, Cleary, Kirstie L, Bodén, Mimoza, Mårtensson, Linda, Foloppe, Johann, Teige, Ingrid, Quéméneur, Eric, Frendéus, Björn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Oncolytic and Local Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8783833/
https://www.ncbi.nlm.nih.gov/pubmed/35058324
http://dx.doi.org/10.1136/jitc-2021-003488

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8783833/
https://www.ncbi.nlm.nih.gov/pubmed/35058324
http://dx.doi.org/10.1136/jitc-2021-003488

Ejemplares similares